BiolaseBIOL
BIOL
Delisted
BIOL was delisted on the 20th of June, 2024.
About: Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
Employees: 157
Financial journalist opinion
Neutral
Accesswire
4 months ago
BIOLASE Voluntarily Initiates Chapter 11 Proceedings
LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to continue operating during the proceedings and remains focused on providing its customers with its award-winning dental lasers and customer service.
Neutral
Accesswire
5 months ago
BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen
LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024. "We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE.
Neutral
Accesswire
7 months ago
BIOLASE Announces Delisting from Nasdaq
LAKE FOREST, CA / ACCESSWIRE / June 18, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced that the Company received a notice from Nasdaq that it has determined to delist the shares of the Company's common stock from The Nasdaq Stock Market. The delisting is a result of failure to satisfy the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) and failure to comply with Nasdaq's $2,500,000 minimum stockholders' equity requirement for continued listing or any of the alternative requirements in Listing Rule 5550(b).
Neutral
Seeking Alpha
8 months ago
BIOLASE, Inc. (BIOL) Q1 2024 Earnings Call Transcript
BIOLASE, Inc. (NASDAQ:BIOL ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Michael Polyviou - Investor Relations John Beaver - President and Chief Executive Officer Jennifer Bright - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Ed Woo - Ascendiant Capital Operator Good day, and welcome to the BIOLASE First Quarter 2024 Results Conference Call. All participants will be in a listen-only mode.
Neutral
Accesswire
8 months ago
Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability
Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and Success LAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024. First Quarter Financial Highlights Generated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialists Third strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptions Gross margin was relatively flat compared to the year-ago quarter; however, it improved by 1% year over year as the Company continues to benefit from 100% of its trunk fiber requirements now being supplied in-house and improved by 7% compared to the prior quarter from inventory adjustments and reserve charges recorded in the fourth quarter ended December 31, 2023 Significantly lowered Adjusted EBITDA loss by 21% versus the same quarter last year, as cost reduction initiatives achieved desired outcomes Full Year 2024 Financial Guidance Reiterates 2024 full-year financial guidance, in which it expects: 2024 full-year net revenue to increase between 6% and 8% year over year to between $52 million and $53 million.
Neutral
Accesswire
9 months ago
BIOLASE to Report First Quarter 2024 Results on May 13, 2024
LAKE FOREST, CA / ACCESSWIRE / May 6, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release first quarter 2024 financial and operating results on Monday, May 13, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.
Neutral
Seeking Alpha
10 months ago
BIOLASE, Inc. (BIOL) Q4 2023 Earnings Call Transcript
BIOLASE, Inc. (BIOL) Q4 2023 Earnings Call Transcript
Neutral
Accesswire
10 months ago
Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024
LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, who previously announced its preliminary financial results for the fourth quarter and full year ended December 31, 2023, today reported its financial results for the quarter and full year. 2023 Full-Year Highlights Achieved revenue growth despite industry headwinds and a challenging interest rate environment throughout 2023.
Neutral
Accesswire
10 months ago
BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024
LAKE FOREST, CA / ACCESSWIRE / March 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.
Neutral
Accesswire
11 months ago
Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry
Waterlase iPlus Premier Edition™ is being unveiled at the Chicago Midwinter Meeting 2024 LAKE FOREST, CA / ACCESSWIRE / February 22, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, has launched its state-of-the-art all-tissue laser system, Waterlase iPlus Premier Edition™, and will be debuting it at the Chicago Midwinter Meeting 2024 from February 22nd to 24th at booth 4608. The Waterlase iPlus Premier Edition™ is an extraordinary update to the industry-leading Waterlase iPlus and represents the pinnacle of innovation in dental care.
Charts implemented using Lightweight Charts™